Pub. Date : 2020 Jul 15
PMID : 32234756
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | TP53 mutations predict sensitivity to adjuvant gemcitabine in patients with pancreatic ductal adenocarcinoma: next-generation sequencing results from the CONKO-001 trial. | gemcitabine | tumor protein p53 | Homo sapiens |
| 2 | In Gem treated patients, TP53 mutations were a positive predictive factor for gemcitabine efficacy (TP53mut: HR for DFS Gem vs Obs: 0.235 (0.130 - 0.423; p<0.001); TP53wt: HR for DFS Gem vs Obs: 0.794 (0.417 - 1.513; p = 0.483) with a significant test for interaction (p=0.003). | gemcitabine | tumor protein p53 | Homo sapiens |
| 3 | In Gem treated patients, TP53 mutations were a positive predictive factor for gemcitabine efficacy (TP53mut: HR for DFS Gem vs Obs: 0.235 (0.130 - 0.423; p<0.001); TP53wt: HR for DFS Gem vs Obs: 0.794 (0.417 - 1.513; p = 0.483) with a significant test for interaction (p=0.003). | gemcitabine | tumor protein p53 | Homo sapiens |
| 4 | In Gem treated patients, TP53 mutations were a positive predictive factor for gemcitabine efficacy (TP53mut: HR for DFS Gem vs Obs: 0.235 (0.130 - 0.423; p<0.001); TP53wt: HR for DFS Gem vs Obs: 0.794 (0.417 - 1.513; p = 0.483) with a significant test for interaction (p=0.003). | gemcitabine | tumor protein p53 | Homo sapiens |
| 5 | CONCLUSION: In CONKO-001, the benefit from adjuvant gemcitabine was confined to the TP53mut patient group. | gemcitabine | tumor protein p53 | Homo sapiens |
| 6 | The sensitivity of TP53mut PDAC to gemcitabine in CONKO-001 provides a lead for further mechanistic investigations. | gemcitabine | tumor protein p53 | Homo sapiens |